Filing Flows › Comparisons › CRDF vs ENTX
Cardiff Oncology vs Entera Bio: CRDF and ENTX compared
Cardiff Oncology is the larger company: $104K of revenue in its latest quarter (Q2 2026) against $42K for Entera Bio (Q1 2025).
Where the money goes: CRDF and ENTX
Cardiff Oncology (CRDF) · Q2 2026
Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Entera Bio (ENTX) · Q1 2025
Entera Bio, Q1 2025: revenue $42K, net loss $2.6M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
| Cardiff Oncology (CRDF) | Entera Bio (ENTX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2025 |
| Revenue | $104K | $42K |
| Revenue growth, Y/Y | -14% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$9.2M | −$2.6M |
| Operating cash flow | −$11.8M | −$1.4M |
Questions
Which is bigger, Cardiff Oncology or Entera Bio?
Cardiff Oncology is the larger company: $104K of revenue in its latest quarter (Q2 2026) against $42K for Entera Bio (Q1 2025).
More: Cardiff Oncology earnings · how Cardiff Oncology makes money · Entera Bio earnings · how Entera Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed May 9, 2025). Fiscal quarters can end on different dates. Not investment advice.